{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:07:04Z","timestamp":1761894424112},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,11,7]],"date-time":"2006-11-07T00:00:00Z","timestamp":1162857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2006,12,14]]},"DOI":"10.1007\/s00277-006-0193-2","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T10:26:28Z","timestamp":1162808788000},"page":"101-105","source":"Crossref","is-referenced-by-count":59,"title":["The hyper-CVAD\u2013rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma"],"prefix":"10.1007","volume":"86","author":[{"given":"D. S.","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,11,7]]},"reference":[{"issue":"5","key":"193_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","volume":"7","author":"P Meusers","year":"1989","unstructured":"Meusers P, Engelhard M, Bartels H et al (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7(5):365\u2013380","journal-title":"Hematol Oncol"},{"issue":"5","key":"193_CR2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS et al (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20(5):1288\u20131294","journal-title":"J Clin Oncol"},{"issue":"11","key":"193_CR3","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","volume":"13","author":"I Teodorovic","year":"1995","unstructured":"Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al (1995) Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin\u2019s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13(11):2819\u20132826","journal-title":"J Clin Oncol"},{"issue":"4","key":"193_CR4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","volume":"85","author":"RI Fisher","year":"1995","unstructured":"Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM (1995) A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a southwest oncology group study. Blood 85(4):1075\u20131082","journal-title":"Blood"},{"key":"193_CR5","unstructured":"Hiddemann W, Unterhalt M, Dreyling M et al (2002) The addition of rituximab to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 100:92a (suppl 1, abstr 339)"},{"issue":"12","key":"193_CR6","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H et al (1998) Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16(12):3803\u20133809","journal-title":"J Clin Oncol"},{"issue":"12","key":"193_CR7","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","volume":"98","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Saliba RM, Okoroji GJ et al (2003) Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 98(12):2630\u20132635","journal-title":"Cancer"},{"issue":"2","key":"193_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","volume":"71","author":"NS Andersen","year":"2003","unstructured":"Andersen NS, Pedersen L, Elonen E et al (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 71(2):73\u201380","journal-title":"Eur J Haematol"},{"issue":"4","key":"193_CR9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F et al (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 16(4):587\u2013593","journal-title":"Leukemia"},{"issue":"7","key":"193_CR10","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 105(7):2677\u20132684","journal-title":"Blood"},{"issue":"2","key":"193_CR11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","volume":"102","author":"AM Gianni","year":"2003","unstructured":"Gianni AM, Magni M, Martelli M et al (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102(2):749\u2013755","journal-title":"Blood"},{"issue":"5","key":"193_CR12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120(5):793\u2013800","journal-title":"Br J Haematol"},{"issue":"28","key":"193_CR13","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA et al (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013\u20137023","journal-title":"J Clin Oncol"},{"issue":"9","key":"193_CR14","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","volume":"17","author":"BS Kahl","year":"2006","unstructured":"Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH (2006) Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 17(9):1418\u20131423","journal-title":"Ann Oncol"},{"key":"193_CR15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0193-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-006-0193-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0193-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T22:41:13Z","timestamp":1587249673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-006-0193-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,7]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,12,14]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1007\/s00277-006-0193-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,7]]}}}